Anti-BCMA antibody-drug conjugate (specialist)
Belantamab mafodotin
Brand names: Blenrep
Adult dose
Dose: 2.5mg/kg IV q3w (per protocol)
Route: IV
Frequency: q3w
Clinical pearls
- NICE TA evaluation (re-introduced via DREAMM-7/8 trials): relapsed/refractory multiple myeloma
- BSH myeloma guidelines
- Mandatory ophthalmic review before each dose; dose adjust for ocular events
Contraindications
- Severe ocular disease
- Pregnancy
- Hypersensitivity
Side effects
- Keratopathy / corneal events (very common — REMS-style ophthalmic monitoring)
- Thrombocytopenia
- Infusion reactions
- Anaemia
- Pneumonia
- Hepatic enzyme elevation
Interactions
- Live vaccines
Monitoring
- Ophthalmic exam pre-dose
- FBC
- LFTs
- Infusion reactions
Reference: BNF; NICE TA evaluation; BSH myeloma; SmPC; https://bnf.nice.org.uk/drugs/belantamab-mafodotin-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Vancomycin Dosing Calculator · Drug Dosing
- Phenytoin Correction for Albumin / Renal Failure · Drug Dosing
- Local Anaesthetic Maximum Dose Calculator · Drug Dosing
- Tisdale Risk Score for QT Prolongation · Arrhythmia
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158